TY - JOUR
T1 - Breathing new life nanomedicines for pulmonary drug delivery
T2 - targeting approaches, experimental models, and regulatory aspects
AU - Gholap, Amol
AU - Pardeshi, Sagar
AU - Giram, Prabhanjan
AU - Nangare, Sopan
AU - Sodha, Shrushti
AU - Kapare, Harshad
AU - More, Mahesh
AU - Sonar, Yogesh
AU - Shukla, Rahul
AU - Naik, Jitendra
AU - Reddy, Gayathri
AU - Damiri, Fouad
AU - Dhas, Namdev
AU - Berrada, Mohammed
AU - Bari, Dipak
AU - Prajapati, Bhupendra
AU - García, Mónica C.
AU - Pardeshi, Chandrakantsing
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: The lungs serve a critical function in air transport and gas exchange, presenting an appealing route for noninvasive drug administration. However, the unique physiology and anatomy of the lungs influence the efficacy and safety of pulmonary drug delivery. A comprehensive approach combining both an optimized pharmaceutical formulation and an appropriate delivery device is essential for effective pulmonary therapies. Main body: Pulmonary drug delivery can achieve both local and systemic effects. During pulmonary drug delivery, several factors viz. particle size, electrostatic charge, inhalation parameters, airway functionality, disease state, and proper use of delivery device must be considered. Current advancements in nanotechnology have led to the development of innovative nanocarriers tailored for pulmonary administration. These nanocarriers offer benefits such as targeted deposition in specific areas of the tracheobronchial tree, controlled drug release, protection of active pharmaceutical ingredients (APIs) from lung clearance mechanisms, and cell-specific targeting. Research on nanomedicine for pulmonary delivery has progressed significantly, resulting in the development of several (nano)formulations, devices, and products in various stages of clinical development, with some already commercially available. Recent studies have focused on improving inhalation device testing, aerosol formulation development, and the application of in vitro, ex vivo, in vivo, and in silico models to better understand pulmonary drug deposition and disposition. Conclusion: This review highlights the anatomical and physiological features of the lungs, recent advances in nanocarrier design and inhalation technologies. In addition, the applications in respiratory and systemic disease management have also been included. While significant progress has been made, challenges remain in optimizing pulmonary drug delivery systems, necessitating further research to address these complexities and enhance the therapeutic outcomes.
AB - Background: The lungs serve a critical function in air transport and gas exchange, presenting an appealing route for noninvasive drug administration. However, the unique physiology and anatomy of the lungs influence the efficacy and safety of pulmonary drug delivery. A comprehensive approach combining both an optimized pharmaceutical formulation and an appropriate delivery device is essential for effective pulmonary therapies. Main body: Pulmonary drug delivery can achieve both local and systemic effects. During pulmonary drug delivery, several factors viz. particle size, electrostatic charge, inhalation parameters, airway functionality, disease state, and proper use of delivery device must be considered. Current advancements in nanotechnology have led to the development of innovative nanocarriers tailored for pulmonary administration. These nanocarriers offer benefits such as targeted deposition in specific areas of the tracheobronchial tree, controlled drug release, protection of active pharmaceutical ingredients (APIs) from lung clearance mechanisms, and cell-specific targeting. Research on nanomedicine for pulmonary delivery has progressed significantly, resulting in the development of several (nano)formulations, devices, and products in various stages of clinical development, with some already commercially available. Recent studies have focused on improving inhalation device testing, aerosol formulation development, and the application of in vitro, ex vivo, in vivo, and in silico models to better understand pulmonary drug deposition and disposition. Conclusion: This review highlights the anatomical and physiological features of the lungs, recent advances in nanocarrier design and inhalation technologies. In addition, the applications in respiratory and systemic disease management have also been included. While significant progress has been made, challenges remain in optimizing pulmonary drug delivery systems, necessitating further research to address these complexities and enhance the therapeutic outcomes.
UR - https://www.scopus.com/pages/publications/105008556586
UR - https://www.scopus.com/pages/publications/105008556586#tab=citedBy
U2 - 10.1186/s43088-025-00646-6
DO - 10.1186/s43088-025-00646-6
M3 - Review article
AN - SCOPUS:105008556586
SN - 2314-8535
VL - 14
JO - Beni-Suef University Journal of Basic and Applied Sciences
JF - Beni-Suef University Journal of Basic and Applied Sciences
IS - 1
M1 - 65
ER -